Literature DB >> 28225519

A Cytokine Pattern That Differentiates Preseroconversion From Postseroconversion Phases of Primary HIV Infection.

Lucia Pastor1, Erica Parker, Jorge Carrillo, Victor Urrea, Laura Fuente-Soro, Durval Respeito, Chenjerai Jairoce, Inacio Mandomando, Julià Blanco, Denise Naniche.   

Abstract

BACKGROUND: During acute HIV infection, HIV actively replicates but seroconversion has not yet occurred. Primary HIV infection (PHI) is characterized by a transient nonspecific febrile illness, a massive inflammatory response, and the progressive appearance of anti-HIV-specific antibodies. In this study, we have identified patterns of inflammatory biomarkers associated with the innate immunological reaction before completion of a full humoral response.
METHODS: A symptom-based screening was used to identify acute HIV infection in the Manhiça District Hospital in Mozambique. Plasma levels of biomarkers were determined by Luminex and enzyme-linked immunosorbent assay. Anti-HIV antibodies were analyzed by flow cytometry and Western blot. Statistical analyses used random forest and logistic regression models.
RESULTS: Of 3116 rapid test seronegative or indeterminate individuals, 85 (2.7%) had positive plasma HIV viral load and were enrolled as PHI, of which n = 45 (52.9%), n = 8 (9.4%), n = 12 (14.1%), and n = 20 (23.5%) were classified as Fiebig I-III, IV, V, and VI stages, respectively, by Western blot. Comparison of individuals at early (Fiebig I-IV) and late (Fiebig V-VI) immune stages identified significant differences in the expression level of plasma B-cell activating factor , monocyte chemotactic protein-1, sCD163, and monokine induced by interferon (IFN-γ). This cytokine signature classified patients in the preseroconversion phase with a sensitivity of 92.5% and a specificity of 81.2%
CONCLUSIONS: : Identification of a cytokine signature specific for the preseroconversion stage of PHI may help to understand the earliest HIV pathogenic events and identify new potential targets for immunotherapy aimed at modulating the cytokine response to HIV infection.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28225519     DOI: 10.1097/QAI.0000000000001272

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  10 in total

Review 1.  Cytokines and chemokines involved in the defense reaction against HIV-1 and hepatitis B virus: isn't it time to use a standardized nomenclature of the involved mediators?

Authors:  Lutz G Gürtler
Journal:  Virus Genes       Date:  2019-12-17       Impact factor: 2.332

2.  Brief Report: HIV-1 Seroconversion Is Not Associated With Prolonged Rectal Mucosal Inflammation.

Authors:  Cheríe S Blair; Jordan E Lake; Ryan C Passaro; Susan Chavez-Gomez; Eddy R Segura; Julie Elliott; Jennifer A Fulcher; Steven Shoptaw; Robinson Cabello; Jesse L Clark
Journal:  J Acquir Immune Defic Syndr       Date:  2021-04-15       Impact factor: 3.771

3.  Dynamics of CD4 and CD8 T-Cell Subsets and Inflammatory Biomarkers during Early and Chronic HIV Infection in Mozambican Adults.

Authors:  Lucía Pastor; Victor Urrea; Jorge Carrillo; Erica Parker; Laura Fuente-Soro; Chenjerai Jairoce; Inacio Mandomando; Denise Naniche; Julià Blanco
Journal:  Front Immunol       Date:  2018-01-05       Impact factor: 7.561

4.  IP-10 Levels as an Accurate Screening Tool to Detect Acute HIV Infection in Resource-Limited Settings.

Authors:  Lucía Pastor; Aina Casellas; Jorge Carrillo; Sergi Alonso; Erica Parker; Laura Fuente-Soro; Chenjerai Jairoce; Inacio Mandomando; Julià Blanco; Denise Naniche
Journal:  Sci Rep       Date:  2017-08-14       Impact factor: 4.379

5.  Evolution of the gut microbiome following acute HIV-1 infection.

Authors:  Muntsa Rocafort; Marc Noguera-Julian; Javier Rivera; Lucía Pastor; Yolanda Guillén; Jost Langhorst; Mariona Parera; Inacio Mandomando; Jorge Carrillo; Víctor Urrea; Cristina Rodríguez; Maria Casadellà; Maria Luz Calle; Bonaventura Clotet; Julià Blanco; Denise Naniche; Roger Paredes
Journal:  Microbiome       Date:  2019-05-11       Impact factor: 14.650

6.  Different pattern of stool and plasma gastrointestinal damage biomarkers during primary and chronic HIV infection.

Authors:  Lucía Pastor; Jost Langhorst; Dorit Schröder; Aina Casellas; Andreas Ruffer; Jorge Carrillo; Victor Urrea; Sergio Massora; Inacio Mandomando; Julià Blanco; Denise Naniche
Journal:  PLoS One       Date:  2019-06-11       Impact factor: 3.240

7.  A Longitudinal Analysis Reveals Early Activation and Late Alterations in B Cells During Primary HIV Infection in Mozambican Adults.

Authors:  Montse Jiménez; Lucía Pastor; Victor Urrea; María Luisa Rodríguez de la Concepción; Erica Parker; Laura Fuente-Soro; Chenjerai Jairoce; Inacio Mandomando; Jorge Carrillo; Denise Naniche; Julià Blanco
Journal:  Front Immunol       Date:  2021-01-15       Impact factor: 7.561

8.  Infection with HIV-1 subtype D among acutely infected Ugandans is associated with higher median concentration of cytokines compared to subtype A.

Authors:  Anne Kapaata; Sheila N Balinda; Jonathan Hare; Olga Leonova; Bernard Kikaire; Moses Egesa; Lawrence Lubyayi; Gladys N Macharia; Anatoli Kamali; Jill Gilmour; Bernard Bagaya; Jesus F Salazar-Gonzalez; Pontiano Kaleebu
Journal:  IJID Reg       Date:  2022-03-10

9.  Differences in acute retroviral syndrome by HIV-1 subtype in a multicentre cohort study in Africa.

Authors:  Eduard J Sanders; Matthew A Price; Etienne Karita; Anatoli Kamali; William Kilembe; Linda-Gail Bekker; Shabir Lakhi; Mubiana Inambao; Omu Anzala; Patricia E Fast; Jill Gilmour; Kimberly A Powers
Journal:  AIDS       Date:  2017-11-28       Impact factor: 4.177

10.  Association between the cytokine storm, immune cell dynamics, and viral replicative capacity in hyperacute HIV infection.

Authors:  Daniel M Muema; Ngomu A Akilimali; Okechukwu C Ndumnego; Sipho S Rasehlo; Raveshni Durgiah; Doty B A Ojwach; Nasreen Ismail; Mary Dong; Amber Moodley; Krista L Dong; Zaza M Ndhlovu; Jenniffer M Mabuka; Bruce D Walker; Jaclyn K Mann; Thumbi Ndung'u
Journal:  BMC Med       Date:  2020-03-25       Impact factor: 8.775

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.